Skinvisible Financials
This page shows Skinvisible (SKVI) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 16 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Financial Health Signals
For every $1 of reported earnings, Skinvisible generates $0.04 in operating cash flow (-$38K OCF vs -$1.1M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
Skinvisible earns $-0.9 in operating income for every $1 of interest expense (-$496K vs $572K). This narrow margin raises concern about the company's ability to service its debt if operating income declines.
Key Financial Metrics
Earnings & Revenue
Skinvisible generated $20K in revenue in fiscal year 2025. This represents an increase of 0.0% from the prior year.
Skinvisible's EBITDA was -$476K in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 16.4% from the prior year.
Skinvisible reported -$1.1M in net income in fiscal year 2025. This represents a decrease of 88.1% from the prior year.
Cash & Balance Sheet
Skinvisible generated -$42K in free cash flow in fiscal year 2025, representing cash available after capex.
Skinvisible had 5M shares outstanding in fiscal year 2025. This represents an increase of 1.6% from the prior year.
Margins & Returns
Skinvisible's gross margin was 100.0% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is up 0.0 percentage points from the prior year.
Skinvisible's operating margin was -2481.6% in fiscal year 2025, reflecting core business profitability. This is up 466.4 percentage points from the prior year.
Skinvisible's net profit margin was -5320.2% in fiscal year 2025, showing the share of revenue converted to profit. This is down 2491.9 percentage points from the prior year.
Capital Allocation
Skinvisible invested $4K in capex in fiscal year 2025, funding long-term assets and infrastructure.
SKVI Income Statement
| Metric | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $5K0.0% | $5K0.0% | $5K0.0% | $5K0.0% | $5K0.0% | $5K0.0% | $5K0.0% | $5K |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | $5K0.0% | $5K0.0% | $5K0.0% | $5K0.0% | $5K0.0% | $5K0.0% | $5K0.0% | $5K |
| R&D Expenses | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| SG&A Expenses | $106K-22.2% | $136K-2.7% | $140K-29.6% | $199K+60.2% | $124K-13.2% | $143K+15.7% | $123K-9.7% | $137K |
| Operating Income | -$106K+22.2% | -$136K+2.6% | -$140K+29.6% | -$199K-59.0% | -$125K+12.4% | -$143K-15.8% | -$123K+9.8% | -$137K |
| Interest Expense | $144K+1.0% | $143K+1.1% | $141K-16.3% | $169K+0.5% | $168K+0.7% | $167K+0.1% | $166K-0.8% | $168K |
| Income Tax | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Income | -$250K+8.8% | -$274K+2.3% | -$281K-189.3% | $315K+209.8% | -$287K+5.6% | -$303K-4.5% | -$290K+4.4% | -$304K |
| EPS (Diluted) | N/A | N/A | N/A | N/A | $-0.06+14.3% | $-0.07-16.7% | $-0.06 | N/A |
SKVI Balance Sheet
| Metric | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $134K-6.8% | $143K-4.1% | $150K-5.5% | $158K+6.4% | $149K-8.8% | $163K+6.3% | $153K-5.8% | $163K |
| Current Assets | $28K-14.0% | $33K-13.6% | $38K-8.9% | $42K+53.4% | $27K-23.6% | $36K+16.9% | $31K-13.5% | $35K |
| Cash & Equivalents | $645+437.5% | $120-99.1% | $13K+29.6% | $10K+1588.9% | $612-91.2% | $7K-13.7% | $8K+811.8% | $888 |
| Inventory | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Receivable | $5K0.0% | $5K+963.8% | $470-90.6% | $5K+400.0% | $1K-80.0% | $5K | N/A | $5K |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $10.1M+2.4% | $9.9M+2.8% | $9.6M+2.6% | $9.4M-6.3% | $10.0M+2.8% | $9.7M+2.9% | $9.5M+3.1% | $9.2M |
| Current Liabilities | $4.8M+5.3% | $4.5M+6.3% | $4.3M+16.4% | $3.7M-21.2% | $4.6M+15.4% | $4.0M-1.7% | $4.1M+16.6% | $3.5M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | -$10.0M-2.6% | -$9.8M-2.9% | -$9.5M-2.8% | -$9.2M+6.5% | -$9.9M-3.0% | -$9.6M-2.9% | -$9.3M-3.2% | -$9.0M |
| Retained Earnings | -$40.8M-0.6% | -$40.5M-0.7% | -$40.2M-0.7% | -$39.9M+0.8% | -$40.3M-0.7% | -$40.0M-0.8% | -$39.7M-0.7% | -$39.4M |
SKVI Cash Flow Statement
| Metric | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $524+105.7% | -$9K+71.0% | -$32K-87.6% | -$17K-34.8% | -$13K+55.3% | -$28K-128.5% | -$12K-219.8% | -$4K |
| Capital Expenditures | -$1 | N/A | N/A | N/A | $0 | N/A | N/A | N/A |
| Free Cash Flow | $523 | N/A | N/A | N/A | -$13K | N/A | N/A | N/A |
| Investing Cash Flow | $1 | N/A | N/A | $0 | $0 | N/A | N/A | $0 |
| Financing Cash Flow | $0 | $0-100.0% | $35K+30.6% | $27K+332.1% | $6K-83.0% | $36K+85.6% | $20K+387.5% | $4K |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
SKVI Financial Ratios
| Metric | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 100.0%0.0pp | 100.0%0.0pp | 100.0%0.0pp | 100.0%0.0pp | 100.0%0.0pp | 100.0%0.0pp | 100.0%0.0pp | 100.0% |
| Operating Margin | -2121.1%+603.6pp | -2724.7%+72.3pp | -2797.0%+1177.8pp | -3974.9%-1475.5pp | -2499.4%+354.5pp | -2853.9%-390.2pp | -2463.7%+267.1pp | -2730.8% |
| Net Margin | -5004.9%+483.6pp | -5488.5%+131.6pp | -5620.1%-11915.5pp | 6295.4%+12027.5pp | -5732.1%+336.9pp | -6069.0%-261.5pp | -5807.4%+268.4pp | -6075.8% |
| Return on Equity | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Assets | -187.3%+4.1pp | -191.4%-3.5pp | -187.9%-386.9pp | 199.0%+391.8pp | -192.8%-6.7pp | -186.1%+3.2pp | -189.3%-2.8pp | -186.5% |
| Current Ratio | 0.010.0 | 0.010.0 | 0.010.0 | 0.010.0 | 0.010.0 | 0.010.0 | 0.010.0 | 0.01 |
| Debt-to-Equity | -1.010.0 | -1.010.0 | -1.020.0 | -1.020.0 | -1.020.0 | -1.020.0 | -1.020.0 | -1.02 |
| FCF Margin | 10.5% | N/A | N/A | N/A | -250.8% | N/A | N/A | N/A |
Similar Companies
Frequently Asked Questions
What is Skinvisible's annual revenue?
Skinvisible (SKVI) reported $20K in total revenue for fiscal year 2025. This represents a 0.0% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Skinvisible's revenue growing?
Skinvisible (SKVI) revenue grew by 0% year-over-year, from $20K to $20K in fiscal year 2025.
Is Skinvisible profitable?
No, Skinvisible (SKVI) reported a net income of -$1.1M in fiscal year 2025, with a net profit margin of -5320.2%.
What is Skinvisible's EBITDA?
Skinvisible (SKVI) had EBITDA of -$476K in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Skinvisible's gross margin?
Skinvisible (SKVI) had a gross margin of 100.0% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is Skinvisible's operating margin?
Skinvisible (SKVI) had an operating margin of -2481.6% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is Skinvisible's net profit margin?
Skinvisible (SKVI) had a net profit margin of -5320.2% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is Skinvisible's free cash flow?
Skinvisible (SKVI) generated -$42K in free cash flow during fiscal year 2025. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Skinvisible's operating cash flow?
Skinvisible (SKVI) generated -$38K in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are Skinvisible's capital expenditures?
Skinvisible (SKVI) invested $4K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
Are Skinvisible's earnings high quality?
Skinvisible (SKVI) has an earnings quality ratio of 0.04x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Skinvisible cover its interest payments?
Skinvisible (SKVI) has an interest coverage ratio of -0.9x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.